Apellis Pharmaceuticals, Inc. - APLS STOCK NEWS

Apellis Pharmaceuticals (APLS) announced positive results from the Phase 3 OAKS and DERBY studies for SYFOVRE™ (pegcetacoplan injection), the first approved treatment for geographic atrophy (GA) due to age-related macular degeneration (AMD). The analyses presented at the ARVO Annual Meeting demonstrated that SYFOVRE preserved visual function, showing a mean advantage of 5.6 letters in best corrected visual acuity compared to sham, and a 4.1-point improvement in quality-of-life scores. Additionally, SYFOVRE significantly slowed the loss of retinal cells necessary for vision, reducing photoreceptor cell loss by 46-53% and retinal pigmented epithelial cell loss by 20-27%. With marketing applications under review in multiple regions, a decision in the EU is anticipated in early 2024.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced that its marketing applications for intravitreal pegcetacoplan, targeted at treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD), have been validated by regulatory bodies in Canada, Australia, the UK, and Switzerland. Decisions from these authorities are anticipated in the first half of 2024. Following its first approval in the U.S., this move marks a significant step towards worldwide access to pegcetacoplan. The applications were based on Phase 3 OAKS and DERBY study results, demonstrating meaningful reductions in GA lesion growth. Additionally, a marketing authorization application is under review by the European Medicines Agency, with an expected decision in early 2024.

Apellis Pharmaceuticals has launched the GA Won’t Wait™ campaign featuring actor Henry Winkler to raise awareness about geographic atrophy (GA), a serious form of age-related macular degeneration (AMD) affecting one million Americans. The initiative aims to educate older adults on recognizing symptoms of GA and encourage them to seek timely medical advice. Winkler draws from personal experience, having witnessed the devastating effects of AMD on his father-in-law's independence. Symptoms of GA include blurred vision and difficulty with daily tasks, emphasizing the need for early diagnosis and intervention. Apellis stresses that vision loss isn't a natural part of aging, and timely eye health discussions are crucial as individuals age. For further details, visit GAwontwait.com.

Apellis Pharmaceuticals (Nasdaq: APLS) announced the approval of equity inducement awards to seven new employees on April 3, 2023. The awards, totaling 16,115 restricted stock units (RSUs), are designed to incentivize new hires as part of their employment acceptance. The RSUs will vest in increments of 25% annually over four years, contingent upon continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's strategy to attract talent in the biopharmaceutical sector, particularly in complement medicine.

As a leader in this field, Apellis aims to innovate therapies for rare and neurological diseases. The company is committed to developing transformative medicines and enhancing its workforce to support ongoing research and development efforts.

Apellis Pharmaceuticals (Nasdaq: APLS) announced on March 6, 2023, the approval of equity awards for six new employees, granted on March 1, 2023. The awards, consisting of 19,495 restricted stock units (RSUs), are part of the 2022 Inducement Stock Incentive Plan and were essential for the employees’ acceptance of their positions. Each RSU will vest in increments of 25% annually, contingent on continuous employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and showcases Apellis’ commitment to attracting talent for advancing its work in complement medicine.

Apellis Pharmaceuticals, a leader in complement medicine, announced its participation in two upcoming March investor conferences:

• Cowen 43rd Annual Healthcare Conference: Fireside chat on March 8, 2023, at 9:10 a.m. ET.
• Oppenheimer’s 33rd Annual Healthcare Conference: Virtual fireside chat on March 13, 2023, at 3:20 p.m. ET.

Both events will have live webcasts available on the company’s website, with replays accessible for 90 days. Apellis focuses on innovative therapies aimed at complex diseases, boasting two approved medications for targeting complement C3. For more details, visit apellis.com.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) has completed its underwritten public offering, raising approximately $402.5 million through the sale of 4,007,936 shares of common stock priced at $63.00 per share, along with pre-funded warrants for 2,380,956 shares. The offering includes an additional 833,333 shares due to underwriters' full exercise of their option. The funds will support Apellis' commitment to developing innovative therapies. J.P. Morgan, Goldman Sachs, and Evercore served as joint book-running managers for the offering, which was facilitated under an automatically effective shelf registration statement.

Apellis Pharmaceuticals (Nasdaq: APLS) announced the pricing of its public offering of 3,174,603 shares of common stock at $63.00 per share, and 2,380,956 pre-funded warrants at $62.9999 each, totaling approximately $350 million gross proceeds before deductions. The offering is set to close on February 27, 2023, pending customary conditions. J.P. Morgan, Goldman Sachs, and Evercore are the joint book-running managers. The securities are offered under an automatically effective shelf registration statement filed with the SEC. This move aims to bolster Apellis's ability to develop innovative therapies targeting serious diseases.

Apellis Pharmaceuticals has initiated an underwritten public offering of $300 million in its common stock, with the possibility of a 15% over-allotment option for underwriters. The offering is managed by J.P. Morgan, Goldman Sachs, and Evercore, and will occur under an automatically effective shelf registration filed with the SEC on February 22, 2023. The final terms will be disclosed in a prospectus supplement. Apellis, recognized for its advancements in complement medicine, aims to leverage the funds for its ongoing development of therapies targeting critical diseases.